Johnson & Johnson (NYSE:JNJ) Issues FY 2025 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 10.500-10.700 for the period, compared to the consensus estimate of 10.600. The company issued revenue guidance of $89.2 billion-$90.0 billion, compared to the consensus revenue estimate of $91.1 billion.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Bank of America dropped their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research note on Friday, January 17th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $173.27.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $148.10 on Wednesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock has a market cap of $356.57 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 2.50 and a beta of 0.51. The stock’s 50 day simple moving average is $148.35 and its two-hundred day simple moving average is $156.11. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.